Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      NEW YORK'S ONLY OUTPATIENT PROGRAM FOR REDUCING ALLERGIC REACTIONS TO CANCER TREATMENTS HITS NEW CARE MILESTONE

      Montefiore Einstein Comprehensive Cancer Center logo (PRNewsfoto/Montefiore Einstein Comprehensive Cancer Center)

      News provided by

      Montefiore Einstein Comprehensive Cancer Center

      May 20, 2024, 08:15 ET

      Share this article

      Share this article


      Montefiore Einstein Comprehensive Cancer Center Celebrates

      200 Outpatient Desensitization Procedures, Enabling Patients to Stay on Optimal Therapy

      NEW YORK, May 20, 2024 /PRNewswire/ -- What happens when you have cancer, but are allergic to the most effective medication to treat your disease?

      Continue Reading
      The Outpatient Chemotherapy Desensitization Program at Montefiore Einstein Comprehensive Cancer Center Enables More Patients to Stay on Optimal Therapy
      The Outpatient Chemotherapy Desensitization Program at Montefiore Einstein Comprehensive Cancer Center Enables More Patients to Stay on Optimal Therapy

      Approximately 10% of people diagnosed with cancer experience hypersensitivity reactions (HSRs) to certain therapies—which range from a mild skin rash to anaphylaxis (a life-threatening allergic reaction)—even when they were pretreated with antihistamines and steroids. To address this issue, patients with HSRs are often referred for chemotherapy desensitization treatment that requires a series of overnight stays in a hospital intensive care unit (ICU).

      The NCI-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) offers a better approach: an outpatient cancer therapy desensitization program. The program—the only one in the New York City area—has completed 200 such procedures, allowing patients to complete optimal treatments within recommended timeframes and avoid the hospital.

      "When someone is diagnosed with cancer, the last thing they need to learn is that they are allergic to the medication that will best treat their disease," says Jessica Oh, M.D., director, Montefiore Drug Allergy Center, assistant professor of medicine at Albert Einstein College of Medicine, and a member of MECCC. "Every patient who has been referred to our program has successfully completed treatment, which is a testament to the close collaboration between allergy, oncology, pharmacy, nursing, and the medical ICU teams. I hope that hitting this milestone demonstrates that outpatient desensitization programs should become the new standard in comprehensive cancer care."

      Cancer Therapy Allergic Reactions & Treatment

      Taxane-based chemotherapies that include Paclitaxel, Docetaxel, Abraxane, and Taxotere are among the most effective and commonly used therapies for several types of cancers, including breast and prostate cancer. They are also widely used to reduce secondary tumors from occurring. These treatments, however, cause allergic reactions in approximately 10% of people.

      Platinum agents, like oxaliplatin, carboplatin, and cisplatin, are effective cancer therapies, used alone and in combination with other drugs. However, up to 25% of the time, people experience allergic reactions to their platinum chemotherapy, typically occurring between the six and ninth cycle of treatment. 

      The chemotherapy desensitization process creates a temporary drug tolerance for each infusion treatment by slowly increasing the doses of drugs every 15 minutes over the course of five to seven hours, depending on the individual patient and the specific cancer drug. This procedure is closely overseen by Dr. Oh and a registered nurse who specializes in chemotherapy infusion treatments, ensuring the patient safely receives each full dose.

      When a patient is identified as potentially having an allergic reaction to a chemotherapy drug, they are referred to the allergy desensitization program for an evaluation, which includes a skin test and a thorough medical history. If a patient is a potential candidate, treatment begins within approximately a week. The chemotherapy desensitization program is available to patients receiving cancer treatment at MECCC or at another treatment center.

      "I had a bad anaphylactic allergic reaction when I started chemotherapy; my blood pressure dropped, my lips went numb, my tongue swelled, and I felt like I was going to pass out," said Virginia Brehaut. "Even though I still had a reaction in the chemotherapy desensitization program, I didn't think twice about it since I was able to get the cancer medicine I needed. I would do anything to fight for my life, and Dr. Oh was my miracle who helped me do that."

      About Montefiore Einstein Comprehensive Cancer Center 

      Montefiore Einstein Comprehensive Cancer Center (MECCC) is a National Cancer Institute (NCI)-designated comprehensive cancer center and a national leader in cancer research and clinical care located in the racially and ethnically diverse borough of the Bronx, N.Y. MECCC combines the exceptional science of Albert Einstein College of Medicine with the multidisciplinary and team-based approach to cancer clinical care at Montefiore Health System. Founded in 1971 and an NCI-designated cancer center since 1972, MECCC is redefining excellence in cancer research, clinical care, education and training, and community outreach and engagement. Its mission is to reduce the burden of cancer for all, especially people from historically underrepresented groups. 

      SOURCE Montefiore Einstein Comprehensive Cancer Center

      Modal title

      Also from this source

      Montefiore Einstein Comprehensive Cancer Center Awarded $10 Million Grant to Investigate Breast Cancer Relapse

      Montefiore Einstein Comprehensive Cancer Center Awarded $10 Million Grant to Investigate Breast Cancer Relapse

      The National Cancer Institute (NCI) has awarded a multidisciplinary and multi-institutional team led by Julio A. Aguirre-Ghiso, Ph.D., of Montefiore...

      EL NOMBRAMIENTO DE NUEVOS LÍDERES ABRE UN NUEVO HORIZONTE EN LA ATENCIÓN E INVESTIGACIÓN DEL CÁNCER

      EL NOMBRAMIENTO DE NUEVOS LÍDERES ABRE UN NUEVO HORIZONTE EN LA ATENCIÓN E INVESTIGACIÓN DEL CÁNCER

      Ulrich Steidl, M.D., Ph.D. ha completado la formación del equipo de líderes de Montefiore Einstein Comprehensive Cancer Center (MECCC), apenas seis...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Hispanic

      Hispanic

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.